Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Effectiveness and Treatment Sequences in Patients With Extensive Stage SCLC Who Received Lurbinectedin as Part of the French Early Access Program (ATU).

NCT05285033 is registered in ClinicalTrials.gov with Intergroupe Francophone de Cancerologie Thoracique as lead sponsor.

NCT NCT05285033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05285033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Effectiveness and Treatment Sequences in Patients With Extensive Stage SCLC Who Received Lurbinectedin as Part of the French Early Access Program (ATU).
Lead sponsor
Intergroupe Francophone de Cancerologie Thoracique
Phase
Observational
Overall status
Completed
Start date
April 1, 2022
Completion date
December 15, 2022
Enrollment
312 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

small-cell lung cancer